Status:
UNKNOWN
Personalized Atrial Fibrillation Ablation With QDOT
Lead Sponsor:
Antonio Berruezo, MD, PhD
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Circumferential pulmonary vein isolation (PVI) has become a mainstay in the treatment of atrial fibrillation (AF), particularly in symptomatic patients with paroxysmal AF (PAF) intolerant or refractor...
Detailed Description
Circumferential pulmonary vein isolation (PVI) has become a mainstay in the treatment of atrial fibrillation (AF), particularly in symptomatic patients with paroxysmal AF (PAF) intolerant or refractor...
Eligibility Criteria
Inclusion
- Age \> 18 years.
- Indication for paroxysmal atrial fibrillation ablation.
- Signed informed consent
Exclusion
- Age \< 18 years.
- Pregnancy.
- Previous AF redo procedure.
- Impossibility to perform a pre-procedural CT scan.
- Concomitant investigation treatments.
- Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2023
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT04298177
Start Date
March 1 2022
End Date
December 30 2023
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Teknon Medical Center
Barcelona, Spain, 08004